acib
acib is a Graz-based, COMET-funded industrial biotechnology research centre that co-develops sustainable processes and technologies for pharmaceutical, chemical and biotech companies, delivering applied R&D, technology offers, licensing and start-up incubation rather than commercial products.
- Company typePrivate
- Founded2002
- HeadquartersGraz, Austria
- Headcount101–250
- GTM typeB2B
- OfferingServices
What acib does
acib GmbH is an Austrian non-profit research centre in industrial biotechnology, registered in Graz (Krenngasse 37/2, A-8010 Graz; company register FN 224687y) and operating since 2002. It develops sustainable, economically and technologically advanced processes for the biotechnology, pharmaceutical and chemical industries, and serves industrial partners ranging from large multinational pharmaceutical and chemical companies (Boehringer Ingelheim, Novartis, Takeda, 3M, BASF, DSM, Clariant, Evonik, Givaudan) to start-ups and small biotechnology companies, with university research groups as a second constituency. Current scale is reported as 200 scientists working on more than 70 industrial cooperative projects across more than eight research disciplines, with 40 industrial partners, more than 70 international partners and access to more than 50 academic partners and 40 university departments.
The technical platform is organised around six research fields: biocatalysis and enzyme technology; innovative products from renewable resources and biorefineries; plant biotechnology; applied biodiversity; sustainable microbial biotechnology; and bioprocess technology, biopharmaceuticals and diagnostics. Downstream capability is an explicit part of the offering, covering continuous and integrated purification, chromatography, virus purification and bionanoparticle process development. Commercially packaged outputs are sold as "technology offers" and cooperation opportunities rather than as products, including one-shot industrial enzyme design (catalytic-motif scaffolding combined with diffusion-based design and atomistic refinement), integrated one-pot enzymatic and microbial conversion of PBAT polyester waste into high-value aromatics, site-specific immobilisation for lectin biosensors, non-invasive real-time monitoring of 3D cell systems, a modular E. coli-based virus-like particle production workflow, a circular fermentation platform converting brewery side streams into DHA, bio-based (R)-10-hydroxystearic acid, fish-cell-culture stabilizers replacing fetal bovine serum, cultivated Mediterranean scallop cell cultures, and the CASPON™ purification tag with scar-free enzymatic tag removal. Underlying research artefacts include explainable deep learning for real-time chromatographic protein A capture monitoring, 'Fedbatchdesigner' for fed-batch optimization, dynamic control flux balance analysis, model predictive control for biopharmaceutical production, and the open PyCoMo and specXplore software packages.
The business model has four revenue streams: industry co-funded collaborative research projects; exploitation of research results through IP, technology offers and licensing; public research funding through the COMET/FFG K2 competence-centre programme plus Horizon Europe and MSCA grants; and start-up and spin-off incubation services. Pricing is quote-based and not publicly disclosed, with economics governed by FFG COMET rules under which company partners bear a total of 50% of project costs and, in four-partner projects, each partner funds one quarter of total research costs. Go-to-market is relationship-led enterprise field sales run by a dedicated business development function, supplemented by a self-serve Cooperation Opportunities and Technology Offers portal, an academic partner network that supplies scientists, supervision and infrastructure, and demand generation through the esib summit, ISPPP conference series, SciTech Impulse webinars, blog, podcast and newsletter. Public research funding covers only part of costs, so the model depends on continuous acquisition of industrial co-funding partners rather than product sales; no revenue figure is disclosed.
acib firmographics
Firmographics- Name
- acib
- Legal name
- acib GmbH
- Website
- https://acib.at
- Company type
- Private
- Founded year
- 2002
- Headcount range
- 101–250 employees
- Short description
- acib is a Graz-based, COMET-funded industrial biotechnology research centre that co-develops sustainable processes and technologies for pharmaceutical, chemical and biotech companies, delivering applied R&D, technology offers, licensing and start-up incubation rather than commercial products.
- Ownership category
- akta.pro rank
acib industry classification
Industry- Product category
- Industrial Biotechnology R&D and Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
Keywords
Where acib is headquartered
LocationHeadquarters
- HQ city
- Graz
- HQ country
- Austria
- HQ region
- Europe
Offices3 records
Markets served
acib business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Industry co-funded collaborative research projects: Non-profit research centre funded publicly through COMET, with industry partners co-financing cooperative industrial research projects. Company partners bear a total of only 50% of project costs under FFG COMET funding, and in multi-company projects each of four company partners pays only a quarter of total research costs. Revenue therefore depends on continuous acquisition of industrial co-funding partners rather than on product sales.
- Exploitation of research results (IP and technology offers): Business purpose of acib GmbH is "research and development in the field of industrial biotechnology as well as the exploitation of research results", with a dedicated Trust & Transparency Center section on IPR, an "acib brand" section and a Technology Offers / Cooperation Opportunities programme that commercialises research results (e.g. (R)-10-hydroxystearic acid, site-specific immobilisation, de novo enzyme design) with IP and confidentiality terms tailored to industrial needs.
- Public research funding (COMET / FFG) and EU project grants: acib is funded as a K2 competence centre through the COMET programme, financed by the Austrian federal ministries and the federal states (Styria/SFG, Vienna, Lower Austria, Tyrol) with professional programme management by the Austrian Research Promotion Agency (FFG); additional income comes from Horizon Europe / MSCA project grants in which acib coordinates or participates in consortia.
- Start-up and spin-off incubation services: As an innovation and incubation centre, acib supports start-ups, spin-offs and centre-based companies with tailored services, know-how and network access, including business-development advice for potential founders and support in finding investors; spin-offs such as Yflavour (meat flavour for alternative proteins) have been created from acib research.
Go-to-market motion5 records
Distribution channels5 records
Marketing channels10 records
acib product offering
Product offeringCore offering
acib GmbH is a non-profit, COMET K2-funded industrial biotechnology research centre in Graz, Austria that develops sustainable, economically and technologically advanced processes for the biotech, pharmaceutical and chemical industries. It sells applied R&D through cooperative industrial research projects co-funded by industry partners, commercialised "Technology Offers" (e.g. de novo enzyme design, site-specific protein immobilisation, PBAT upcycling, (R)-10-hydroxystearic acid, E. coli-based VLP production), and applied science services (ethics support, DACCORD® consortium facilitation, dissemination and communication), organised across six research fields: biocatalysis and enzyme technology, biorefineries/renewable resources, plant biotechnology, applied biodiversity, sustainable microbial biotechnology, and bioprocess technology/biopharmaceuticals and diagnostics.
Product overview
acib is not a single commercial product but a non-profit, COMET-funded research centre and Open Innovation platform offering applied industrial biotechnology R&D as a one-stop-shop for industry partners. Its offering is organised around named research fields (Biocatalysis & Enzyme Technology; Innovative Products from Renewable Resources/Biorefineries; Plant Biotechnology; Applied Biodiversity; Sustainable Microbial Biotechnology; Bioprocess Technology, Biopharmaceuticals and Diagnostics), a portfolio of commercialised Technology Offers (Real-Time Monitoring for 3D Cell Systems, Bio-based (R)-10-Hydroxystearic Acid, E. coli Shortcut to Affordable VLPs, Affordable DHA Without Fish Oil or Algae, Beyond Ovulation: Toward Smart Fertility Tests, Stabilizers for Fish Cell Culture, Integrated PBAT Upcycling, Cultivated Mediterranean Scallop, Perfectly Positioned Lectin BioSensors and One-Shot Industrial Enzyme Design), and applied science services for academia (Ethics in R&I, Fast & Fair Consortium Agreements with DACCORD®, Dissemination & Communication). These elements are combined with EU- and industry-funded research projects (BeyondBattRec, CAARE, Piezo4Spine, ConCO2rde, CirculH2, FEASTS, BiocatCodeExpander) and shared state-of-the-art biotechnological infrastructure, so the individual technology offers and service modules plug into shared research competence, IP and infrastructure rather than forming one unified software product.
Differentiator
Problem solved
Functional benefit
Products and services
- Real-Time Monitoring for 3D Cell Systems Non-invasive, real-time monitoring technology for 3D cellular systems, which better mimic a physiological environment than 2D culture but are hard to monitor without destroying the tissue; offered to biopharmaceutical and cell-culture researchers as a technology offer.
- E. coli Shortcut to Affordable VLPs Modular E. coli-based workflow for virus-like particle production that addresses cost, speed and scalability bottlenecks in VLP manufacturing for targeted delivery, vaccines and nanobiotechnology.
- Beyond Ovulation: Toward Smart Fertility Tests Smart diagnostic concept that uses the cervical environment as a biofluid to determine whether it is sperm-friendly at the right moment, extending fertility testing beyond ovulation alone.
- Integrated PBAT Upcycling One-pot enzymatic and microbial conversion process that upcycles PBAT waste and similar polyesters into high-value aromatics, addressing the shortage of efficient recycling routes for these plastics.
- Perfectly Positioned Lectin BioSensors Site-specific protein immobilization technology that orients lectins consistently on sensor surfaces, improving signal intensity, background and reproducibility versus random immobilization.
- Bio-based (R)-10-Hydroxystearic Acid Sustainable biotechnological production route for (R)-10-hydroxystearic acid, a compound valued in dermatological and cosmetic applications for its moisturizing, thickening and stabilizing properties and traditionally produced by chemical synthesis.
- Affordable DHA Without Fish Oil or Algae Circular fermentation platform converting brewery side streams into docosahexaenoic acid (DHA), targeting maternal and child nutrition with a cheaper source than fish oil or algae.
- Stabilizers for Fish Cell Culture Stabilizers designed to remove the need for costly animal-derived fetal bovine serum (FBS) in fish cell culture, supporting the sustainable cellular aquaculture sector.
- Cultivated Mediterranean Scallop Establishment of robust primary cell cultures from Pecten jacobaeus plus species-fit media and supplements that support controlled growth and future cell line development for safer, season-independent seafood.
- One-Shot Industrial Enzyme Design De novo enzyme design service that goes from target reaction to decision-ready catalysts in one compact cycle by combining catalytic-motif scaffolding with diffusion design and atomistic refinement.
- CASPON™ Purification Tag with Scar-Free Tag Removal Proprietary affinity tag with broad physicochemical stability for recombinant protein production and purification, whose removal by the CASPON™ enzyme leaves no scar, demonstrated in a case study of five proteins.
- Ethics in R&I: Strategic Support for Responsible Science Expert support for values, compliance and impact in EU and international research and innovation projects, embedding ethics at the heart of research design and proposal work.
- Fast & Fair Consortium Agreements – Facilitation with DACCORD® Facilitation service using the DACCORD® method to streamline complex multi-partner negotiations and help consortia reach agreements efficiently, transparently and on time.
- Dissemination & Communication Scientific dissemination and communication support that makes industrial biotechnology results visible to the public, offered to researchers and project partners.
- HDX-MS (Hydrogen-Deuterium Exchange coupled to Mass Spectrometry) Analysis Analytical technology offered to partners for rapid insight into protein conformation and dynamics.
- Biocatalysis & Enzyme Technology Core research field covering biocatalysis and enzyme technology, including one-pot enzymatic cascades and enzyme engineering for industrial chemical synthesis.
- Innovative Products from Renewable Resources / Biorefineries Research field for value creation from renewable and waste resources, covering bio-based materials, recycling loops for textiles and bio-based plastics, and circular biorefineries.
- Plant Biotechnology Research field on plant-cell-based production platforms, including molecular farming for pharmaceuticals and production of plant alkaloids in bioreactors.
- Applied Biodiversity Research field applying biodiversity and microbiome functions to industrial problems such as microbiome-based agriculture, microbiome-inspired next-generation probiotics and plastic degradation by carnivorous plants.
- Sustainable Microbial Biotechnology Research field covering microbial biotechnology and synthetic biology of yeast, bacteria and filamentous fungi, CO2/H2-based bioproduction and autotrophic gas fermentation.
- Bioprocess Technology, Biopharmaceuticals and Diagnostics Research field spanning cell line development, animal cell technology, downstream processing, bionanoparticles, viral vectors and diagnostic method development.
- acib Open Innovation Platform Open Innovation approach used by acib to combine internal and external ideas, generating new ideas, products, services or business models and supporting the incubation of start-ups, spin-offs and center-based companies.
Companies that use acib
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles5 records
acib technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature12 records
acib partnerships and signals
Strategic signalPartnerships
26 partnerships are on record, tiered core, flagship and minor.
- BeyondBattRec (EU project 101193032)coreHorizon Europe funded project (2024–2028) on beyond state-of-the-art battery recycling by increasing selectivity and specificity of efficient pre-processing technologies; acib GmbH is responsible for the project website and media line.
- FEASTScoreCollaborative research programme (2024–2026) building an unbiased knowledge base about cultured meat and seafood (CM/CSF) and its place in the food system.
- Piezo4Spine (EU project 101098597)coreHorizon Europe funded project (2023–2026) developing a novel multifactorial therapy for spinal cord injury, targeting Piezo mechanoreceptors (mechanotransduction) and meningeal fibroblasts (inhibitory scarring); acib runs the project website and a dedicated newsletter category.
- ConCO2rde (EU project 955740)coreMSCA-ITN training network (2021–2025) training Early Stage Researchers to convert CO2 in smart autotrophic biorefineries; acib is responsible for the project website and media line.
- ENZYCLE (EU project 887913)coreBBI-JU Horizon Europe project (2020–2024) on enzymatic degradation of plastic fractions that could not be recycled before; acib runs the dedicated project website.
- CODOBIO (EU project 812909)coreMSCA-ITN European Training Network (2019–2023) on continuous downstream processing of biologics, coordinated by acib; acib is responsible for the project website and media line.
- Hotzymes (EU project 829162)coreFETOPEN project (2019–2022) realising biocatalytic cascades in one pot by coupling enzymes to magnetic nanoparticles so that temperature optima can be locally controlled via an alternate magnetic field; acib is responsible for the project website.
- Universität für Bodenkultur Wien (BOKU)flagshipShareholder of acib GmbH with 39% of the company. BOKU scientists supervise acib research groups (e.g. Prof. Johannes Buyel, Prof. Brigitte Gasser, Prof. Gerald Striedner) and BOKU locations in Vienna and Tulln host acib projects such as algae-based skin care ingredients and sterile 3D-printed lab equipment.
- Technische Universität Graz (TU Graz)flagshipShareholder of acib GmbH with 39%. TU Graz professors (e.g. Prof. Harald Pichler) lead acib research areas, and university framework contracts underpin jointly conducted industrial projects.
- Karl-Franzens-Universität GrazcoreShareholder of acib GmbH with 13%, contributing academic research capacity and supervision of PhD theses within acib's cooperative industrial projects.
- Joanneum Research Forschungsgesellschaft mbHcoreShareholder of acib GmbH with 9%, an Austrian applied research organisation that contributes to acib's industrial biotechnology research and innovation activities.
- Boehringer IngelheimcoreMajor international pharmaceutical company that has been part of the acib partner network for many years, working together on a sustainable circular economy.
- 3McoreMajor international company from the pharmaceutical industry named as a long-standing member of the acib partner network, collaborating toward a sustainable circular economy.
- NovartiscoreMajor international pharmaceutical company that has been part of the acib partner network for many years and works together on a sustainable circular economy.
- TakedacoreMajor international pharmaceutical company named as part of the acib partner network, collaborating with the centre on sustainable circular economy projects.
- ClariantcoreRenowned player from the chemical sector that has been part of the acib partner network for many years, cooperating on sustainable circular economy initiatives.
- BASFcoreRenowned chemical-sector player in the acib partner network for many years, working together on bio-based circular economy projects.
- DSMcoreRenowned biotechnology/chemicals player in the acib partner network for many years, collaborating on sustainable circular economy development.
- EvonikcoreRenowned chemical-sector player within the acib partner network, cooperating on sustainable circular economy programmes.
- GivaudancoreRenowned player from the chemical sector in the acib partner network for many years, working with the centre on sustainable circular economy topics including bio-based flavours and fragrances.
- BiocatCodeExpander (MSCA Doctoral Network)coreDoctoral Network expanding the diversity of functional groups present in proteins to enhance biocatalysis and biotechnology by using non-canonical amino acids as building blocks.
- OLINWASTE (EU project 101181402)minorHorizon Europe Innovation Action project on smart sustainable biorefining of olive mill waste into biocompounds for plant and soil health, bioplastics and bioenergy; acib is responsible for the project website and media line.
- Bio2Project (EU project 101181331)minorHorizon Europe Innovation Action project on natural biomass and microbial biocontrol agent solutions for the replacement of contentious inputs in organic farming; acib is responsible for the project website and media line.
- Yflavourcoreacib spin-off company whose mission is to make alternative protein products delicious and tasty by providing natural and healthy meat flavour, originating from acib research.
- Mailchimp (The Rocket Science Group, LLC)minorMarketing platform used by acib to distribute its free newsletters (Events, Technology Offers, Biotech News, Career and project categories) using double opt-in; subscriber data is processed in the US under EU standard contractual clauses.
- world4youminorHosting provider for all acib websites (acib.at, esib.at, codobio.eu, hotzymes.eu and other project and event sites listed in the privacy statement); acib publishes the provider's own data-protection declaration.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
acib competitors and assessment
Company assessmentDirect peers
- NIBRT (National Institute for Bioprocess Industry and Training): A non-profit applied research and training institute that co-develops bioprocessing, cell-line and downstream technologies with industrial pharma and biotech partners under collaborative, co-funded projects — structurally very close to acib's cooperative industrial research and tech-transfer model.
- BioCat – German Industrial Biotechnology Cluster: A German industry-facing cluster and competence network for industrial and white biotechnology, connecting companies with academic biocatalysis, bioprocess and biobased-chemistry research — the same industry-academic open-innovation bridge role acib plays in Austria.
- CLIB – Cluster Industrial Biotechnology: A European cluster of industrial biotechnology companies and research partners focused on industrial enzymes, biorefineries and biocatalysis, competing for the same corporate R&D budgets and consortium projects that acib's cooperative projects target.
- VTT Technical Research Centre of Finland: A national applied research institute running industrial biotechnology, bioprocessing and circular-economy programmes for industry, with a comparable portfolio of co-funded collaborative projects, pilots and spin-outs.
Emerging players
- c-LEVER GmbH: A specialist computational biocatalyst and enzyme-screening company serving pharma, flavour and fine-chemical clients with rapid enzyme discovery — directly overlapping acib's enzyme discovery and screening technology offer for industrial partners.
- Schrödinger, Inc. A physics- and AI-driven computational platform company that commercialises de novo enzyme design and structure prediction, competing for the same discovery budgets that acib addresses with its one-shot industrial enzyme design offering.
Broad incumbents
- Ginkgo Bioworks: A synthetic-biology 'foundry' that builds and tests engineered cell programmes for industrial partners; it overlaps acib's strain engineering and bioprocess development work but delivers via a commercial, software-led platform rather than a research centre.
- Codexis, Inc. A commercial enzyme-engineering and protein-optimisation company serving pharma and industrial customers, competing with acib's biocatalysis, protein immobilisation and biomanufacturing technology offers but with a fully commercial model and IP-protected product portfolio.
- Novonesis: The world's largest industrial enzymes company, supplying the same enzyme and biocatalysis market acib's chemical and materials clients buy, and a potential customer or competitor for acib's enzyme engineering IP.
- Lonza Group: A global CDMO with leading expertise in mammalian cell culture and downstream processing, overlapping the biopharmaceutical and bioprocess technology field in which acib runs cooperative projects with pharma partners such as Novartis, Takeda and Boehringer Ingelheim.
Market position
Strengths5 records
Weaknesses6 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
acib social profiles
Digital presenceacib compliance and trust
Trust signalCompliance1 record
acib financial estimates
Financial estimateRevenue estimate
Valuation estimate
acib leadership team
Management profileNumber of profiles
Profiles15 records
acib funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
acib M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about acib
What does acib do?
acib GmbH is a non-profit, COMET K2-funded industrial biotechnology research centre in Graz, Austria that develops sustainable, economically and technologically advanced processes for the biotech, pharmaceutical and chemical industries. It sells applied R&D through cooperative industrial research projects co-funded by industry partners, commercialised "Technology Offers" (e.g. de novo enzyme design, site-specific protein immobilisation, PBAT upcycling, (R)-10-hydroxystearic acid, E. coli-based VLP production), and applied science services (ethics support, DACCORD® consortium facilitation, dissemination and communication), organised across six research fields: biocatalysis and enzyme technology, biorefineries/renewable resources, plant biotechnology, applied biodiversity, sustainable microbial biotechnology, and bioprocess technology/biopharmaceuticals and diagnostics.
Is acib a public or private company?
acib is a private company. It is classified as nonprofit foundation owned.
When was acib founded?
acib was founded in 2002. It employs 101 to 250 people.
Where is acib based?
acib is headquartered in Graz, Austria, in the Europe region.
How does acib make money?
Four revenue lines are on record. Industry co-funded collaborative research projects are the primary driver. The others are exploitation of research results (IP and technology offers), public research funding (COMET / FFG) and EU project grants and start-up and spin-off incubation services.
Who are acib's main competitors?
Direct peers on record are NIBRT (National Institute for Bioprocess Industry and Training), BioCat – German Industrial Biotechnology Cluster, CLIB – Cluster Industrial Biotechnology and VTT Technical Research Centre of Finland. Emerging players are c-LEVER GmbH and Schrödinger, Inc.. Broad incumbents are Ginkgo Bioworks, Codexis, Inc., Novonesis and Lonza Group.
Does acib have an API?
No public API is recorded for acib.
What industry is acib in?
acib's product category is Industrial Biotechnology R&D and Contract Research Services. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of EUAAAIAL, Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids). Its NAICS code is 541714 and its SIC code is 8731.